During the activation stage of T cells, the concurrent administration of CTLA-4 and PD-L1 inhibitors synergistically enhances the continuous and accelerated activation of effector T cells, facilitating their extensive proliferation and migration towards the tumor microenvironment [39]. This evidence concerns the gene CTLA4 and neoplasm.